Zanzalintinib

Zanzalintinib combined with nivolumab demonstrated a 63% objective response rate and 90% disease control rate in previously untreated advanced clear cell renal cell carcinoma patients.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

Final analysis of COSMIC-313 phase 3 trial demonstrates sustained progression-free survival benefit with cabozantinib-nivolumab-ipilimumab combination in advanced RCC patients.

Exelixis has presented encouraging data at the ASCO Gastrointestinal symposium for their treatment approach in metastatic colorectal cancer (mCRC), particularly for non-liver metastases. The combination of zanzalintinib and atezolizumab has shown improved efficacy compared to existing treatments, with analysts projecting a potential $1 billion market opportunity.

Phase 1b/2 STELLAR-001 trial data shows zanzalintinib combined with atezolizumab improves outcomes in metastatic colorectal cancer (CRC).